Merck & Co. Overview

  • Year Founded
  • 1891

Year Founded

  • Status
  • Public

  • Employees
  • 72,000

Employees

  • Stock Symbol
  • MRK

Stock Symbol

  • Investments
  • 91

  • Share Price
  • $126.88
  • (As of Tuesday Closing)

Merck & Co. General Information

Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Contact Information

Website
www.merck.com
Formerly Known As
Schering Plough
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NYS
Corporate Office
  • 126 East Lincoln Avenue
  • PO Box 2000
  • Rahway, NJ 07065
  • United States
+1 (908) 000-0000

Merck & Co. Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Merck & Co. Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$126.88 $126.94 $99.14 - $133.10 $321B 2.53B 8.31M $0.14

Merck & Co. Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 302,399,197 302,399,197 300,538,183 210,082,343
Revenue 60,115,000 60,115,000 59,283,000 48,704,000
EBITDA 6,542,000 6,542,000 21,158,000 17,863,000
Net Income 365,000 365,000 14,519,000 13,049,000
Total Assets 106,675,000 106,675,000 109,160,000 105,694,000
Total Debt 35,055,000 35,055,000 30,691,000 33,102,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Merck & Co. Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merck & Co.‘s full profile, request access.

Request a free trial

Merck & Co. Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabo
Pharmaceuticals
Rahway, NJ
72,000 As of 2023
000.00
000000000 000.00

000

ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incidi
000000000000000
Middlesex, United Kingdom
00000 As of 0000
000.00
000000000 000.00

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labo
000000000000000
New York, NY
00000 As of 0000
000.00
0000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Merck & Co. Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GSK Corporation Middlesex, United Kingdom 00000 000.00 000000000 000.00
Pfizer (Pharmaceuticals) Corporation New York, NY 00000 000.00 0000 000.00
AstraZeneca Formerly PE-Backed Cambridge, United Kingdom 00000 000.00 000000000 00 000.00
Gilead Sciences Formerly VC-backed Foster City, CA 00000 000.00 0000
Bristol-Myers Squibb Private Debt Financed Princeton, NJ 00000 000.00 000000000 000.00
You’re viewing 5 of 50 competitors. Get the full list »

Merck & Co. Executive Team (87)

Name Title Board Seat Contact Info
Robert Davis JD Chief Executive Officer, Chairman and Board Member
Richard DeLuca Jr. Executive Vice President & President
Sanat Chattopadhyay Executive Vice President & President, Manufacturing
Jannie Oosthuizen President & Senior Vice President
Caroline Litchfield Chief Financial Officer, Finance & Executive Vice President
You’re viewing 5 of 87 executive team members. Get the full list »

Merck & Co. Board Members (25)

Name Representing Role Since
000000000 0000000 Self Board Member 000 0000
0000000 00000 00. Merck & Co. Board Member 000 0000
0000 000000 Merck & Co. Board Member 000 0000
00000 000000 Self Board Member 000 0000
0000 000 Self Board Member 000 0000
You’re viewing 5 of 25 board members. Get the full list »

Merck & Co. Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Merck & Co. Investments & Acquisitions (91)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Abceutics 05-Apr-2024 0000000000 00000 Drug Delivery
Harpoon Therapeutics 11-Mar-2024 0000000000 00000 Drug Discovery
Elanco Aqua 05-Feb-2024 0000000000 00.00 Pharmaceuticals 0000000 0
Evaxion Biotech 21-Dec-2023 0000 00.00 Biotechnology
Caraway Therapeutics 21-Nov-2023 Merger/Acquisition 00000 Drug Discovery 000000 00
You’re viewing 5 of 91 investments and acquisitions. Get the full list »

Merck & Co. Subsidiaries (13)

Company Name Industry Location Founded
Organon & Co. Pharmaceuticals Jersey City, NJ 2021
MRL Ventures Fund Corporate Venture Capital Cambridge, MA 0000
Harpoon Therapeutics Drug Discovery South San Francisco, CA 0000
Peloton Therapeutics Pharmaceuticals Dallas, TX 0000
Merck Global Health Innovation Fund Corporate Venture Capital Kenilworth, NJ 0000
You’re viewing 5 of 13 subsidiaries. Get the full list »

Merck & Co. ESG

Risk Overview

Risk Rating

Updated January, 17, 2024

22.13 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,173

Rank

00.0

Percentile

Pharmaceuticals

Industry

00 of 909

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 444

Rank

0.00

Percentile

To view Merck & Co.’s complete esg history, request access »

Merck & Co. Exits (28)

Company Name Exit Date Exit Type Exit Size Status Buyers
Kelun Biotech 29-Dec-2022 00000 00000 00 00000 Completed
  • 9 buyers
Vence 16-Mar-2022 00000 00000 00 Completed
  • 5 buyers
Lava Therapeutics 17-Sep-2020 00000 00000 00 0000 Completed
  • 10 buyers
Yumanity Therapeutics 24-Jun-2020 00000 00000 00 000.00 Completed
  • 7 buyers
4D pharma 18-Feb-2020 PIPE 000.00 Completed
  • 2 buyers
You’re viewing 5 of 28 exits. Get the full list »

Merck & Co. FAQs

  • When was Merck & Co. founded?

    Merck & Co. was founded in 1891.

  • Who is the CEO of Merck & Co.?

    Robert Davis JD is the CEO of Merck & Co..

  • Where is Merck & Co. headquartered?

    Merck & Co. is headquartered in Rahway, NJ.

  • What is the size of Merck & Co.?

    Merck & Co. has 72,000 total employees.

  • What industry is Merck & Co. in?

    Merck & Co.’s primary industry is Pharmaceuticals.

  • Is Merck & Co. a private or public company?

    Merck & Co. is a Public company.

  • What is Merck & Co.’s stock symbol?

    The ticker symbol for Merck & Co. is MRK.

  • What is the current stock price of Merck & Co.?

    As of 23-Apr-2024 the stock price of Merck & Co. is $126.88.

  • What is the current market cap of Merck & Co.?

    The current market capitalization of Merck & Co. is $321B.

  • What is Merck & Co.’s current revenue?

    The trailing twelve month revenue for Merck & Co. is $60.1B.

  • Who are Merck & Co.’s competitors?

    GSK, Pfizer (Pharmaceuticals), AstraZeneca, Gilead Sciences, and Bristol-Myers Squibb are some of the 50 competitors of Merck & Co..

  • What is Merck & Co.’s annual earnings per share (EPS)?

    Merck & Co.’s EPS for 12 months was $0.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »